Vertex’s Pain Drug Journavx Breaks Through US FDA Communications Freeze

The FDA announcement of the novel, non-opioid drug’s approval highlights public health implications, which probably helped it clear the communication’s freeze. Recent website updates and forthcoming Federal Register notices suggest the freeze could be thawing slowly.